RPRX
NASDAQRoyalty Pharma plc
Price$55.88+8.45 (+17.82%)
2026-03-042026-06-05
News · 26 weeks71-67%
2025-12-142026-06-07
Mix3290d
- Insider12(38%)
- SEC Filings8(25%)
- Other6(19%)
- Leadership2(6%)
- M&A2(6%)
- Earnings2(6%)
Latest news
25 items- SECSEC Form 8-K filed by Royalty Pharma plc8-K - Royalty Pharma plc (0001802768) (Filer)
- PRRoyalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare ConferenceNEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 4:00 p.m. ET. The webcast will be accessible from Royalty Pharma's "Events" page at https://www.royaltypharma.com/investors/events/. Webcasts will also be archived for a minimum of thirty days. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profi
- INSIDEREVP & CFO Coyne Terrance P. sold $3,476,116 worth of Class A Ordinary Shares (64,399 units at $53.98) as part of a pre-agreed trading plan (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- SECRoyalty Pharma plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - Royalty Pharma plc (0001802768) (Filer)
- INSIDEREVP, Research & Investments Urist Marshall sold $721,838 worth of Class A Ordinary Shares (13,684 units at $52.75) as part of a pre-agreed trading plan, decreasing direct ownership by 43% to 18,197 units (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDERDirector Norden Gregory sold $161,385 worth of Class A Ordinary Shares (3,045 units at $53.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 191,803 units (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDEREVP, Research & Investments Urist Marshall sold $726,137 worth of Class A Ordinary Shares (13,684 units at $53.06) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 31,881 units (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- SECSEC Form 144 filed by Royalty Pharma plc144 - Royalty Pharma plc (0001802768) (Subject)
- SECSEC Form 13F-NT filed by Royalty Pharma plc13F-NT - Royalty Pharma plc (0001802768) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Royalty Pharma plcSCHEDULE 13G/A - Royalty Pharma plc (0001802768) (Subject)
- INSIDERCEO, Chairman of the Board Legorreta Pablo G. was granted 143,821 units of Class A Ordinary Shares, increasing direct ownership by 13% to 1,242,604 units (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDEREVP & CFO Coyne Terrance P. was granted 24,263 units of Class A Ordinary Shares (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDEREVP & Vice Chairman Hite Christopher was granted 24,263 units of Class A Ordinary Shares (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDEREVP, Research & Investments Urist Marshall was granted 18,197 units of Class A Ordinary Shares, increasing direct ownership by 66% to 45,565 units (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- PRRoyalty Pharma to present at upcoming investor conferencesNEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: BofA Securities 2026 Healthcare Conference on Wednesday, May 13 at 1:40 p.m. ET / 10:40 a.m. PTRBC Capital Markets 2026 Global Healthcare Conference on Tuesday, May 19 at 10:00 a.m. ET The webcasts will be accessible from Royalty Pharma's "Events" page at https://www.royaltypharma.com/investors/events/. Webcasts will also be archived for a minimum of thirty days. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innov
- SECSEC Form 10-Q filed by Royalty Pharma plc10-Q - Royalty Pharma plc (0001802768) (Filer)
- SECRoyalty Pharma plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Royalty Pharma plc (0001802768) (Filer)
- PRRoyalty Pharma reports first quarter 2026 resultsPortfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13%Net cash provided by operating activities of $718 millionRaised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million to $3,450 million NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the first quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. "Royalty Pharma has delivered a strong start to 2026 across multiple dimensions. We grew Royalty Receipts by 13% and announced up to $1.25 billion of royalty transactions in the first quarter," said Pablo Legorreta, Royalty Pharma's Chief Executive Officer a
- INSIDEREVP & CFO Coyne Terrance P. sold $1,731,840 worth of Class A Ordinary Shares (34,791 units at $49.78) as part of a pre-agreed trading plan (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- PRRoyalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific InnovationNEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in translational medicine. The Prize will honor scientific breakthroughs that bridge the gap between fundamental discovery and the development of new medicines that improve and extend patients' lives. It will include a $1 million award distributed among one or more established scientists whose work has translated unique scientific insights into medicines with significant impact, particularly contributions not yet recognized by the field's most prominent awards. "Royalty Pharma believes that scientific
- PRRoyalty Pharma Declares Second Quarter 2026 DividendNEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Roya
- PRRoyalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma Founded in 1996, Royalty Pharma is th
- SECSEC Form 8-K filed by Royalty Pharma plc8-K - Royalty Pharma plc (0001802768) (Filer)
- SECSEC Form DEFA14A filed by Royalty Pharma plcDEFA14A - Royalty Pharma plc (0001802768) (Filer)
- SECSEC Form DEF 14A filed by Royalty Pharma plcDEF 14A - Royalty Pharma plc (0001802768) (Filer)
RPRX FAQ
7 questionsWhat does Royalty Pharma plc do?
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 45 marketed therapies and 9 development-stage product candidates that...Where does RPRX stock trade?
Royalty Pharma plc (RPRX) is listed on NASDAQ.What sector and industry is RPRX in?
Royalty Pharma plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Royalty Pharma plc go public?
Royalty Pharma plc (RPRX) completed its IPO in 2020.What are analysts saying about RPRX?
Royalty Pharma plc has had 8 recent analyst actions on file. The most recent action was from UBS: Buy with a $4900.00 price target on 2026-01-30. Recent price targets range from $2800.00 to $4900.00.What companies are similar to RPRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare RPRX side-by-side with any of them on Quantisnow.How can I track RPRX on Quantisnow?
Quantisnow aggregates Royalty Pharma plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RPRX to receive live email and push alerts on every new disclosure.